ABT-450: a novel agent for the treatment of CHC genotype 1: focus on treatment-experienced patients

Chronic hepatitis C (CHC) constitutes a major health concern. Hepatitis C virus eradication by antiviral treatment can markedly reduce the risk of developing cirrhosis, hepatocellular carcinoma and liver-related death. A plethora of new direct antiviral agents have been developed and are being explored in clinical trials. One of the newest members of this family is the NS3/4A protease inhibitor ABT-450. The multi-targeted approach combining ritonavir-enhanced ABT-450 with ombitasvir and dasabuvir has been evaluated for the treatment of CHC Gt1 in treatment-naïve and treatment-experienced adults. In this article, we sought to discuss the current knowledge on ABT-450-containing regimens, with special emphasis on treatment-experienced CHC Gt1 patients. This new combination was found to be potent, safe and well tolerated. Future Phase III trials with larger sample size in patients with decompensated cirrhosis, non-Gt1, end-stage renal disease and liver transplant recipients are eagerly awaited.     

Nucleos(t)ide analogues for the treatment of chronic hepatitis B: a systematic review with network meta-analysis

ABSTRACT

Objectives

Chronic hepatitis B (CHB) is a major global health problem caused by hepatitis B virus (HBV) infection, and can put patients at high risk of death from cirrhosis and liver cancer. However, CHB can be treated with nucleos(t)ide analogues. We aimed to evaluate the effectiveness and safety of nucleos(t)ide analogues for the treatment of CHB patients.     

Antimicrobial susceptibility testing (AST): A review of changing trends,quality control guidelines,test accuracy,and recommendation for the testing of β-lactam drugs

The review that follows presents the changing trends in antimicrobial susceptibility testing observed from the author's clinical laboratory experience and the proficiency testing surveys of the College of American Pathologists (CAP). The CAP Microbiology Surveys show a clear trend toward standardized test methods of the National Committee for Clinical Laboratory Standard (NCCLS) and greater compliance with specified methods' technical steps. This has favorably inlfuenced the laboratory performance on proficiency challenges where a 3–5% improvement has been noted over the last 5 years for the disk tests (overall acceptable rate of 95.2% in 1981). A concurrent increase in dilution test use, mainly broth microdilution methods, has resulted in > 25% of larger hospital laboratories reporting results as MICs (overall acceptable or good performance = 98%). Automated systems use also continues to increase, with user performance being monitored at an acceptable level.Quality control frequency may be reduced to once weekly without compromising test accuracy or patient care, but only after adequate daily or concurrent QC performance has been documented. Most methods continue to have problems in testing enterococci, methicillin-resistant staphylococci, and the class-disk concept appears to be less applicable. Recommendations are made for the testing of the newer semisynthetic penicillins and cephalosporins based on their spectrum comparability and cross-resistance studies with bacteria possessing known susceptibility or resistance mechanisms. The concept of “spectrum-class” is introduced with peer drugs within classes.The general trends and quality of antimicrobial susceptibility tests seem outstanding and point toward continued excellent intra- and interlaboratory reproducibility at the national level, primarily due to the efforts of the inspection and accreditation agencies, CAP, CDC, and other concerned professional groups.